{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lemm EA"],"funding":["Cancer Research UK","Worldwide Cancer Research","Kay Kendall Leukaemia Fund","Blood Cancer UK","Southampton Experimental Cancer Medicine and Cancer Research Centres"],"pagination":["1700-1711"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7124891"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(7)"],"pubmed_abstract":["<h4>Purpose</h4>PI3K signaling is a common feature of B-cell neoplasms, including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL), and PI3K inhibitors have been introduced into the clinic. However, there remains a clear need to develop new strategies to target PI3K signaling. PI3K activity is countered by Src homology domain 2-containing inositol-5'-phosphatase 1 (SHIP1) and, here, we have characterized the activity of a novel SHIP1 activator, AQX-435, in preclinical models of B-cell malignancies.<h4>Experimental design</h4><i>In vitro</i> activity of AQX-435 was evaluated using primary CLL cells and DLBCL-derived cell lines. <i>In vivo</i> activity of AQX-435, alone or in combination with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, was assessed usi"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells."],"pmcid":["PMC7124891"],"funding_grant_id":["23669","UNCE/MED/016","16004","14045","16003","13-0267","C24563/A15581","GACR17-14007S","A18087","A23669","C34999/A18087","KKL0168","18009","29370","C2750/A23669","A15581"],"pubmed_authors":["Stevenson FK","Karolova J","Lemm EA","Gebreselassie Y","Carter MJ","Harwig C","Forconi F","Steele AJ","Karydis L","Cragg M","Williamson CT","Valle-Argos B","Richter J","Helman K","Weston-Bell NJ","Cross J","Klener P","Pettigrew J","Mackenzie L","Packham G","Smith LD","Svaton M","Lenz G"],"additional_accession":[]},"is_claimable":false,"name":"Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.","description":"<h4>Purpose</h4>PI3K signaling is a common feature of B-cell neoplasms, including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL), and PI3K inhibitors have been introduced into the clinic. However, there remains a clear need to develop new strategies to target PI3K signaling. PI3K activity is countered by Src homology domain 2-containing inositol-5'-phosphatase 1 (SHIP1) and, here, we have characterized the activity of a novel SHIP1 activator, AQX-435, in preclinical models of B-cell malignancies.<h4>Experimental design</h4><i>In vitro</i> activity of AQX-435 was evaluated using primary CLL cells and DLBCL-derived cell lines. <i>In vivo</i> activity of AQX-435, alone or in combination with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, was assessed usi","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Apr","modification":"2025-04-05T13:25:38.121Z","creation":"2020-10-08T07:16:09Z"},"accession":"S-EPMC7124891","cross_references":{"pubmed":["31831562"],"doi":["10.1158/1078-0432.CCR-19-2202","10.1158/1078-0432.ccr-19-2202"]}}